Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CBFB_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CBFB_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CBFB_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CBFB_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CBFB_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CBFB_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002240724 | Oral cavity | NEOLP | regulation of cell-cell adhesion | 81/2005 | 448/18723 | 1.54e-06 | 3.83e-05 | 81 |
GO:000715923 | Oral cavity | NEOLP | leukocyte cell-cell adhesion | 70/2005 | 371/18723 | 1.65e-06 | 4.05e-05 | 70 |
GO:004211031 | Oral cavity | NEOLP | T cell activation | 86/2005 | 487/18723 | 2.01e-06 | 4.77e-05 | 86 |
GO:190313122 | Oral cavity | NEOLP | mononuclear cell differentiation | 77/2005 | 426/18723 | 2.80e-06 | 6.41e-05 | 77 |
GO:000164931 | Oral cavity | NEOLP | osteoblast differentiation | 47/2005 | 229/18723 | 8.59e-06 | 1.66e-04 | 47 |
GO:000716223 | Oral cavity | NEOLP | negative regulation of cell adhesion | 57/2005 | 303/18723 | 1.62e-05 | 2.79e-04 | 57 |
GO:190370632 | Oral cavity | NEOLP | regulation of hemopoiesis | 66/2005 | 367/18723 | 1.67e-05 | 2.83e-04 | 66 |
GO:190303723 | Oral cavity | NEOLP | regulation of leukocyte cell-cell adhesion | 61/2005 | 336/18723 | 2.56e-05 | 4.01e-04 | 61 |
GO:003009821 | Oral cavity | NEOLP | lymphocyte differentiation | 66/2005 | 374/18723 | 3.08e-05 | 4.67e-04 | 66 |
GO:000268331 | Oral cavity | NEOLP | negative regulation of immune system process | 73/2005 | 434/18723 | 6.18e-05 | 8.22e-04 | 73 |
GO:005086323 | Oral cavity | NEOLP | regulation of T cell activation | 58/2005 | 329/18723 | 9.33e-05 | 1.15e-03 | 58 |
GO:002240923 | Oral cavity | NEOLP | positive regulation of cell-cell adhesion | 51/2005 | 284/18723 | 1.50e-04 | 1.72e-03 | 51 |
GO:190303923 | Oral cavity | NEOLP | positive regulation of leukocyte cell-cell adhesion | 42/2005 | 239/18723 | 8.66e-04 | 6.83e-03 | 42 |
GO:004663112 | Oral cavity | NEOLP | alpha-beta T cell activation | 30/2005 | 156/18723 | 1.06e-03 | 8.05e-03 | 30 |
GO:004663412 | Oral cavity | NEOLP | regulation of alpha-beta T cell activation | 22/2005 | 104/18723 | 1.33e-03 | 9.53e-03 | 22 |
GO:005087023 | Oral cavity | NEOLP | positive regulation of T cell activation | 38/2005 | 216/18723 | 1.45e-03 | 1.03e-02 | 38 |
GO:004663512 | Oral cavity | NEOLP | positive regulation of alpha-beta T cell activation | 16/2005 | 67/18723 | 1.56e-03 | 1.10e-02 | 16 |
GO:190210523 | Oral cavity | NEOLP | regulation of leukocyte differentiation | 46/2005 | 279/18723 | 1.98e-03 | 1.33e-02 | 46 |
GO:003021721 | Oral cavity | NEOLP | T cell differentiation | 43/2005 | 257/18723 | 2.05e-03 | 1.36e-02 | 43 |
GO:190210721 | Oral cavity | NEOLP | positive regulation of leukocyte differentiation | 29/2005 | 157/18723 | 2.40e-03 | 1.53e-02 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CBFB | SNV | Missense_Mutation | | c.394N>A | p.Ala132Thr | p.A132T | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CBFB | SNV | Missense_Mutation | | c.201N>T | p.Gln67His | p.Q67H | Q13951 | protein_coding | tolerated(0.55) | probably_damaging(0.962) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CBFB | SNV | Missense_Mutation | novel | c.220N>A | p.Gln74Lys | p.Q74K | Q13951 | protein_coding | tolerated(0.74) | benign(0.031) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CBFB | SNV | Missense_Mutation | | c.362N>A | p.Gly121Asp | p.G121D | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CBFB | SNV | Missense_Mutation | | c.188A>T | p.Asn63Ile | p.N63I | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CBFB | SNV | Missense_Mutation | | c.296N>T | p.Ala99Val | p.A99V | Q13951 | protein_coding | tolerated(0.16) | probably_damaging(0.961) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CBFB | SNV | Missense_Mutation | | c.311N>G | p.Asn104Ser | p.N104S | Q13951 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-BH-A0EA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | CR |
CBFB | SNV | Missense_Mutation | | c.306N>G | p.Ile102Met | p.I102M | Q13951 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CBFB | SNV | Missense_Mutation | | c.104N>C | p.Arg35Pro | p.R35P | Q13951 | protein_coding | deleterious(0) | benign(0.01) | TCGA-E2-A15C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
CBFB | SNV | Missense_Mutation | | c.167N>G | p.Ala56Gly | p.A56G | Q13951 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-E2-A1L9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CYTARABINE HYDROCHLORIDE | CYTARABINE HYDROCHLORIDE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PURPUROGALLIN | PURPUROGALLIN | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PHENANTHROLINE | PHENANTHROLINE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CY-208243 | CHEMBL313737 | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | FUSARIC ACID | FUSARIC ACID | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PYROGALLOL | PYROGALLOL | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | QUINOLINIC ACID | QUINOLINIC ACID | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | L-NOREPINEPHRINE | L-NOREPINEPHRINE | |
865 | CBFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | IRIGINOL HEXAACEATATE | IRIGINOL HEXAACEATATE | |